THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST-CANCER IN POSTMENOPAUSAL WOMEN

被引:1264
作者
COLDITZ, GA
HANKINSON, SE
HUNTER, DJ
WILLETT, WC
MANSON, JE
STAMPFER, MJ
HENNEKENS, C
ROSNER, B
SPEIZER, FE
机构
[1] BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA
[2] HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA
[3] HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA
[4] HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA
关键词
D O I
10.1056/NEJM199506153322401
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is controversial. Methods. To quantify the relation between the use of hormones and the risk of breast cancer in postmenopausal women, we extended our follow-up of the participants in the Nurses' Health Study to 1992. The women were asked to complete questionnaires every two years to update information on their menopausal status, use of estrogen and progestin preparations, and any diagnosis of breast cancer. During 725,550 person-years of follow-up, we documented 1935 cases of newly diagnosed invasive breastcancer. Results. The risk of breast cancer was significantly increased among women who were currently using estrogen alone (relative risk, 1.32; 95 percent confidence interval, 1.14 to 1.54) or estrogen plus progestin (relative risk, 1.41; 95 percent confidence interval, 1.15 to 1.74), as compared with postmenopausal women who had never used hormones. Women currently taking hormones who had used such therapy for 5 to 9 years had an adjusted relative risk of breast cancer of 1.46 (95 percent confidence interval, 1.22 to 1.74), as did those currently using hormones who had done so for a total of 10 or more years (relative risk, 1.46; 95 percent confidence interval, 1.20 to 1.76). The increased risk of breast cancer associated with five or more years of postmenopausal hormone therapy was greater among older women (relative risk for women 60 to 64 years old, 1.71; 95 percent confidence interval, 1.34 to 2.18). The relative risk of death due to breast cancer was 1.45 (95 percent confidence interval, 1.01 to 2.09) among women who had taken estrogen for five or more years. Conclusions. The addition of progestins to estrogen therapy does not reduce the risk of breast cancer among postmenopausal women, The substantial increase in the risk of breast cancer among older women who take hormones suggests that the trade-offs between risks and benefits should be carefully assessed.
引用
收藏
页码:1589 / 1593
页数:5
相关论文
共 34 条
[1]   THE RISK OF BREAST-CANCER AFTER ESTROGEN AND ESTROGEN PROGESTIN REPLACEMENT [J].
BERGKVIST, L ;
ADAMI, HO ;
PERSSON, I ;
HOOVER, R ;
SCHAIRER, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (05) :293-297
[2]   MENOPAUSAL ESTROGENS AND BREAST-CANCER RISK - AN EXPANDED CASE-CONTROL STUDY [J].
BRINTON, LA ;
HOOVER, R ;
FRAUMENI, JF .
BRITISH JOURNAL OF CANCER, 1986, 54 (05) :825-832
[3]   THE EPIDEMIOLOGY OF SERUM SEX-HORMONES IN POSTMENOPAUSAL WOMEN [J].
CAULEY, JA ;
GUTAI, JP ;
KULLER, LH ;
LEDONNE, D ;
POWELL, JG .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1989, 129 (06) :1120-1131
[4]   BIOLOGIC EFFECTS OF TRANSDERMAL ESTRADIOL [J].
CHETKOWSKI, RJ ;
MELDRUM, DR ;
STEINGOLD, KA ;
RANDLE, D ;
LU, JK ;
EGGENA, P ;
HERSHMAN, JM ;
ALKJAERSIG, NK ;
FLETCHER, AP ;
JUDD, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (25) :1615-1620
[5]   HORMONE REPLACEMENT THERAPY AND RISK OF BREAST-CANCER - RESULTS FROM EPIDEMIOLOGIC STUDIES [J].
COLDITZ, GA ;
EGAN, KM ;
STAMPFER, MJ .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 168 (05) :1473-1480
[6]   TYPE OF POSTMENOPAUSAL HORMONE USE AND RISK OF BREAST-CANCER - 12-YEAR FOLLOW-UP FROM THE NURSES HEALTH STUDY [J].
COLDITZ, GA ;
STAMPFER, MJ ;
WILLETT, WC ;
HUNTER, DJ ;
MANSON, JE ;
HENNEKENS, CH ;
ROSNER, BA ;
SPEIZER, FE .
CANCER CAUSES & CONTROL, 1992, 3 (05) :433-439
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]   THE WANING EFFECT OF POSTMENOPAUSAL ESTROGEN THERAPY ON OSTEOPOROSIS [J].
ETTINGER, B ;
GRADY, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (16) :1192-1193
[10]  
FEINLEIB M, 1968, JNCI-J NATL CANCER I, V41, P315